GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVTU) » Definitions » Change In Other Working Capital

Immunovant (Immunovant) Change In Other Working Capital : $-1.21 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant Change In Other Working Capital?

Immunovant's Change In Other Working Capital for the quarter that ended in Dec. 2023 was $-0.31 Mil. It means Immunovant's Other Working Capital declined by $0.31 Mil from Sep. 2023 to Dec. 2023 .

Immunovant's Change In Other Working Capital for the fiscal year that ended in Mar. 2023 was $-1.15 Mil. It means Immunovant's Other Working Capital declined by $1.15 Mil from Mar. 2022 to Mar. 2023 .


Immunovant Change In Other Working Capital Historical Data

The historical data trend for Immunovant's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Change In Other Working Capital Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23
Change In Other Working Capital
- - -0.80 -1.18 -1.15

Immunovant Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.29 -0.30 -0.31 -0.31

Immunovant Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovant Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Immunovant's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovant (Immunovant) Business Description

Industry
Traded in Other Exchanges
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
W Bradford Middlekauff officer: General Counsel 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Pamela Ann Connealy officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Robert K Zeldin officer: Chief Medical Officer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Health Sciences Holdings, Llc 10 percent owner 412 WEST 15TH STREET, FLOOR 9, NEW YORK NY 10011